TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03656614

Intervention type: DRUG
Intervention: Sugammadex
Description: At the end of surgical procedure at a depth of neuromuscular blockade at the reappearance of train-of-four 0.3, single intravenous injection of either :~Sugammadex 0.125 mg/kg (sugammadex 0.125) Sugammadex 0.25 mg/kg (sugammadex 0.25) Sugammadex 0.5 mg/kg (sugammadex 0.5) Sugammadex 1.0 mg/kg (sugammadex 1.0) Sugammadex 2.0 mg/kg (sugammadex 2.0)

Intervention type: DRUG
Intervention: Sugammadex
Description: At the end of surgical procedure at a depth of neuromuscular blockade at the reappearance of train-of-four 0.3, single intravenous injection of either :~Sugammadex 0.125 mg/kg (sugammadex 0.125) Sugammadex 0.25 mg/kg (sugammadex 0.25) Sugammadex 0.5 mg/kg (sugammadex 0.5) Sugammadex 1.0 mg/kg (sugammadex 1.0) Sugammadex 2.0 mg/kg (sugammadex 2.0)

Intervention type: DRUG
Intervention: Sugammadex
Description: At the end of surgical procedure at a depth of neuromuscular blockade at the reappearance of train-of-four 0.3, single intravenous injection of either :~Sugammadex 0.125 mg/kg (sugammadex 0.125) Sugammadex 0.25 mg/kg (sugammadex 0.25) Sugammadex 0.5 mg/kg (sugammadex 0.5) Sugammadex 1.0 mg/kg (sugammadex 1.0) Sugammadex 2.0 mg/kg (sugammadex 2.0)

Intervention type: DRUG
Intervention: Sugammadex
Description: At the end of surgical procedure at a depth of neuromuscular blockade at the reappearance of train-of-four 0.3, single intravenous injection of either :~Sugammadex 0.125 mg/kg (sugammadex 0.125) Sugammadex 0.25 mg/kg (sugammadex 0.25) Sugammadex 0.5 mg/kg (sugammadex 0.5) Sugammadex 1.0 mg/kg (sugammadex 1.0) Sugammadex 2.0 mg/kg (sugammadex 2.0)

Intervention type: DRUG
Intervention: Sugammadex
Description: At the end of surgical procedure at a depth of neuromuscular blockade at the reappearance of train-of-four 0.3, single intravenous injection of either :~Sugammadex 0.125 mg/kg (sugammadex 0.125) Sugammadex 0.25 mg/kg (sugammadex 0.25) Sugammadex 0.5 mg/kg (sugammadex 0.5) Sugammadex 1.0 mg/kg (sugammadex 1.0) Sugammadex 2.0 mg/kg (sugammadex 2.0)

Intervention type: DRUG
Intervention: Neostigmine
Description: At the end of surgical procedure at a depth of neuromuscular blockade at the reappearance of train-of-four 0.3, single intravenous injection of either :~Neostigmine 10 µg/kg (Neostigmine 10) Neostigmine 25 µg/kg (Neostigmine 25) Neostigmine 40 µg/kg (Neostigmine 40) Neostigmine 55 µg/kg (Neostigmine 55) Neostigmine 70 µg/kg (Neostigmine 70)~Atropine will be administered with Neostigmine at a half dose of Neostigmine administered through an intravenous line with brisk flow.
Study: NCT02396927

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: 2D HD laparoscopy
Description: Placebo
Study: NCT03656614

Intervention type: DRUG
Intervention: Neostigmine
Description: At the end of surgical procedure at a depth of neuromuscular blockade at the reappearance of train-of-four 0.3, single intravenous injection of either :~Neostigmine 10 µg/kg (Neostigmine 10) Neostigmine 25 µg/kg (Neostigmine 25) Neostigmine 40 µg/kg (Neostigmine 40) Neostigmine 55 µg/kg (Neostigmine 55) Neostigmine 70 µg/kg (Neostigmine 70)~Atropine will be administered with Neostigmine at a half dose of Neostigmine administered through an intravenous line with brisk flow.

Intervention type: DRUG
Intervention: Neostigmine
Description: At the end of surgical procedure at a depth of neuromuscular blockade at the reappearance of train-of-four 0.3, single intravenous injection of either :~Neostigmine 10 µg/kg (Neostigmine 10) Neostigmine 25 µg/kg (Neostigmine 25) Neostigmine 40 µg/kg (Neostigmine 40) Neostigmine 55 µg/kg (Neostigmine 55) Neostigmine 70 µg/kg (Neostigmine 70)~Atropine will be administered with Neostigmine at a half dose of Neostigmine administered through an intravenous line with brisk flow.

Intervention type: DRUG
Intervention: Neostigmine
Description: At the end of surgical procedure at a depth of neuromuscular blockade at the reappearance of train-of-four 0.3, single intravenous injection of either :~Neostigmine 10 µg/kg (Neostigmine 10) Neostigmine 25 µg/kg (Neostigmine 25) Neostigmine 40 µg/kg (Neostigmine 40) Neostigmine 55 µg/kg (Neostigmine 55) Neostigmine 70 µg/kg (Neostigmine 70)~Atropine will be administered with Neostigmine at a half dose of Neostigmine administered through an intravenous line with brisk flow.

Intervention type: DRUG
Intervention: Neostigmine
Description: At the end of surgical procedure at a depth of neuromuscular blockade at the reappearance of train-of-four 0.3, single intravenous injection of either :~Neostigmine 10 µg/kg (Neostigmine 10) Neostigmine 25 µg/kg (Neostigmine 25) Neostigmine 40 µg/kg (Neostigmine 40) Neostigmine 55 µg/kg (Neostigmine 55) Neostigmine 70 µg/kg (Neostigmine 70)~Atropine will be administered with Neostigmine at a half dose of Neostigmine administered through an intravenous line with brisk flow.

Intervention type: DRUG
Intervention: Saline 0.9%
Description: At the end of surgical procedure at a depth of neuromuscular blockade at the reappearance of train-of-four 0.3, single intravenous injection of saline 0.9%.
Study: NCT04176705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Cream
Description: Both sites will have lidocaine 4% topical anesthetic cream (Ferndale Laboratories, Ferndale MI) applied as thin layer and left for 30-45 minutes to minimize discomfort applied before laser treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine Cream
Description: Both sites will have lidocaine 4% topical anesthetic cream (Ferndale Laboratories, Ferndale MI) applied as thin layer and left for 30-45 minutes to minimize discomfort applied before laser treatment.
Study: NCT00515216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Study: NCT01256060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Oxytocin
Description: We are selecting morning and afternoon dosing to try to influence most hours where youth are in settings with increased potential for social interaction (school, after school). Medication will be administered by the parents before school and early afternoon. All patients will receive their first dose by the study physician to educate parents and themselves on proper administration and determine safety of first dose.
Study: NCT00842816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ST101
Description: 10 mg; administered once/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ST101
Description: 60 mg; administered once/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ST101
Description: 120 mg; administered once/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo tablets to match ST101 tablets
Study: NCT01086969

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate (Menactra®)
Description: 0.5 mL, Intramuscular
Study: NCT03721887

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: A consecutive 5-days course of tDCS will be delivered. In treatment group, true stimulation will be administrated and sham stimulation will be delivered in control group.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: A consecutive 5-days course of tDCS will be delivered. In treatment group, true stimulation will be administrated and sham stimulation will be delivered in control group.
Study: NCT01746654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P128-0.1 mg
Description: P-128 at 0.1 mg divided evenly between the nares is administered once in Part A; multiple times in Part B and Part C; and once in Part D.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P128-0.3 mg
Description: P-128 at 0.3 mg divided evenly between the nares is administered once in Part A; multiple times in Part B and Part C; and once in Part D.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P128-1.0 mg
Description: P-128 at 1.0 mg divided evenly between the nares is administered once in Part A; multiple times in Part B and Part C; once in Part D.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was administered to both nares once in part A, multiple times in Part B and Part C, Once in part D
Study: NCT03998462

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Based Stress Reduction
Description: MBSR consists of 6-10 individuals with PD and led by a trained instructor who is not involved in the clinical care or assessment of these participants.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Creative Education Care
Description: Creative Education Care consists of 6-10 individuals with PD and led by a trained instructor who is not involved in the clinical care or assessment of these participants.
Study: NCT04176705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide Cream
Description: Triamcinolone acetonide cream (Bristol-Myers Squibb, Princeton, NJ) at a concentration of 20mg/ml will be applied immediately after treatment to both laser and no-laser sites - as this is often reported and there is some speculation that this may be part of the reason improvement is noted.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Triamcinolone Acetonide Cream
Description: Triamcinolone acetonide cream (Bristol-Myers Squibb, Princeton, NJ) at a concentration of 20mg/ml will be applied immediately after treatment to both laser and no-laser sites - as this is often reported and there is some speculation that this may be part of the reason improvement is noted.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractional Ablative Laser
Description: Applied to only site that is randomized to laser intervention
Study: NCT04072354

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet dosed once daily
Study: NCT01366222

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: food concentrates: fruit, vegetable, fish oil and probiotics
Description: comparison the effect of food concentrate

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: food concentrates: fruit, vegetable, fish oil and probiotics
Description: comparison the effect of food concentrate
Study: NCT01279538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bleselumab
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bleselumab
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bleselumab
Description: Intravenous (IV) infusion
Study: NCT00718731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSI-136
Study: NCT01362192

Intervention type: DEVICE
Group type: OTHER
Intervention: 532 nm KTP Excel V Laser, manufactured by Cutera, Inc.
Description: The 532 nm KTP Excel V laser treatment parameters to be used in this study are as follows:~* Spot Size: 5 mm~* Fluence: 13-15 J/cm2~* Pulse Duration: 40 ms~* Epidermal contact-cooling: 5° Celsius
Study: NCT00718731

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00456365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pravastatin
Description: Pravastatin 20 mg daily (subject age 8-12 years) or 40 mg daily (subject age 13-21 years)
Study: NCT01468103

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Iridectomy
Description: Surgical Iridectomy is now widely used in our clinical.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Iridectomy
Description: Surgical Iridectomy is now widely used in our clinical.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser Iridotomy
Description: alternative choice to surgical iridectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser Iridotomy
Description: alternative choice to surgical iridectomy
Study: NCT01860781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paliperidone palmitate
Description: paliperidone palmitate 150mgeq(1 day), 100mgeq(8days), 75mg(monthly)
Study: NCT01254903

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery (SSRS)
Description: Target dose of 18 or 24 Gy to spine in single session of radiation treatment.
Study: NCT00456365

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo daily
Study: NCT01558505

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEB
Description: paclitaxel-eluting balloon angioplasty
Study: NCT04093349

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SPK-3006
Description: adeno-associated viral (AAV) vector
Study: NCT01558505

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: POBA
Description: conventional balloon angioplasty
Study: NCT00091897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab or placebo
Description: A fixed dose of Rituximab or placebo 1GM on Day 1 and 1GM on day 15 (+/- 2 days)
Study: NCT03275831

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PluroGel
Description: Surfactant based gel

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intrasite gel
Description: Hydrogel
Study: NCT02395328

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care Worker Home Visitation
Description: Primary services include biweekly home visits from Care Workers trained, mobilized and supported by Futures Families, a South African non-government organization working to support OVC in six townships within the greater Tshwane area (also known as Pretoria) of South Africa.
Study: NCT02951819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: For induction therapy cycle 1 day 1 and day 2 doses of daratumumab will be 8 milligram/kilogram (mg/kg). Starting cycle 1 week 2 until the completion of week 8 of daratumumab patients will receive 16 mg/kg Intravenously (IV) weekly.~Starting week 9 until the completion of week 24 therapy daratumumab will be administered every other week at 16 mg/kg IV.~Starting week 25 and beyond for induction therapy daratumumab will be given once every 4 weeks.
Study: NCT01279538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bleselumab
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous (IV) infusion
Study: NCT01540344

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CRS
Description: complete macroscopic cytoreduction (CC-0/1)
Study: NCT01821170

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate
Description: Patient will take treatment during two months

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cognitive remediation
Description: Patient will have 12 sessions during 6 to 8 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: supportive psychotherapy
Description: Patients will have 12 sessions during 6 to 8 weeks
Study: NCT01540344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIPEC
Description: bidirectional hyperthermic intraperitoneal chemotherapy (HIPEC) with 400 mg/sqm 5-FU + 20 mg/sqm folinic acid IV and 300 mg/sqm oxaliplatin IP
Study: NCT01545739

Intervention type: DEVICE
Intervention: Evia/Entovis HF-T pacemaker for CRT therapy
Description: Implantation of CRT pacemaker and standard follow-ups at pre-hospital discharge, and after 1, 3 and 6 months
Study: NCT01023061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abiraterone acetate
Description: Given PO
Study: NCT01821170

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neuropsychological tests
Description: neuropsychological tests will assess attentional and executive performance
Study: NCT01023061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leuprolide acetate
Description: Given via injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative study

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: external beam radiation therapy
Description: Undergo radiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: goserelin acetate
Description: Given via injection
Study: NCT03391115

Intervention type: BEHAVIORAL
Intervention: Storytelling Intervention for Patient Participants
Description: The storytelling intervention consists of an audio-recorded interview with each patient participant prompted the participant to share their story with questions such as: tell me about your illness, tell me how your illness has affected your emotions, relationships, and spirituality. The interview transcripts will be used to co-create a 1 page patient story using these criteria:1) written in the first person; 2) nonjudgmental; 3) captures the participant's voice; 4) accurately reflects content of the interview; and 5) non-labeling. Once the story has been approved by the participant, I will upload it to the EHR.

Intervention type: BEHAVIORAL
Intervention: Storytelling Intervention for Nurse Participants
Description: Once the patient's story is uploaded to the EHR, automatic alerts will be sent to the participant's EHR-assigned nurses. For usability testing, nurse participants will 1) provide content expertise of the workflow processes, and 2) put the storytelling intervention through in-house usability testing to check the strength of EHR features and user-friendliness. Data will be collected with exit interviews and completion of a questionnaire: the System Usability Scale which asks them to rank their satisfaction with specific elements such as: how the story is labeled and presented in the EHR, any technical navigation EHR difficulties, and use of the material.
Study: NCT04022941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Benzoate
Description: Group A will receive drug packets containing 2.5 gm sodium benzoate and 5 gm powdered table sugar for 5 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Powdered table sugar as palcebo
Description: Group B will receive 7.5 gm packets of powdered table sugar for 5 days as placebo which is similar in appearance and taste as sodium benzoate.
Study: NCT04600739

Intervention type: PROCEDURE
Intervention: TAVI
Description: Replacement of the aortic valve using a biological prosthesis that is inserted via a catheter.
Study: NCT01711567

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tenofovir
Description: tenofovir 300 mg qd

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: entecavir
Description: entecavir 0.5 mg qd
Study: NCT02627274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6874281
Description: RO6874281 will be administered as per the schedule specified under arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6874281
Description: RO6874281 will be administered as per the schedule specified under arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6874281
Description: RO6874281 will be administered as per the schedule specified under arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab will be administered as per the schedule specified under arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab will be administered as per the schedule specified under arm description.
Study: NCT02310841

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ANGELAA
Description: Different control strategies with transfemoral prosthesis prototype ANGELAA, developed at the Sensory-Motor Systems Lab, ETH Zurich, not commercially available, only 1 device exists
Study: NCT01602380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: faslodex 500mg
Description: 2 x intramuscular injections at day 1, 14, 28 and every 28 days thereafter

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: arimidex 1mg
Description: oral tablet 1 daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: faslodex dummy
Description: 2 x intramuscular injections at day 1, 14, 28 and every 28 days thereafter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arimidex dummy
Description: oral tablet 1 daily
Study: NCT02951819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Subjects will receive 4 to 8 cycles of oral cyclophosphamide 300 milligram per meter square (mg/m\^2 ) on Days 1, 8, 15, and 22 for every 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Subjects will receive 4 to 8 cycles of Bortezomib 1.5 mg/m2 subcutaneous (SC) on Days 1, 8, and 15 for every 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Subjects will be given corticosteroids (Dexamethasone) as pre-infusion therapy prior to daratumumab and for the first 8 cycles will also receive post-infusion corticosteroids (Dexamethasone).
Study: NCT03278041

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Submental flap for palatal reconstruction
Description: Under General Anesthesia the tumor in the maxilla will be resected (partial maxillectomy) with a safety margin, then the defect will be reconstructed immediately by :~Submental artery flap : from submental area with 1 cm distance from inferior mandibular border in paddle shape.~* 1st step will be identify the facial artery and vein,~* 2nd step dissection and extend toward midline in subplatsmal plane. The flap contains submental artery and vein.~* 3rd step creating submucous tunnel between vestibular border of post maxillectomy defect and to extraoral incision .~The flap will be through the oral cavity and will be anchored to the intact remaining hard plate with bone sutures by 2-0 vicryl® suture.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: maxillary obturator
Description: immediate surgical obturator